Epigenetic Reader Domain
All Product Categories
-
Epigenetic Reader Domain Inhibitors
(341)
View all products
-
Epigenetic Reader Domain Agonists
(2)
View all products
-
Epigenetic Reader Domain Antagonists
(2)
View all products
-
Epigenetic Reader Domain Activators
(3)
View all products
-
Epigenetic Reader Domain Modulators
(2)
View all products
-
Epigenetic Reader Domain Chemicals
(2)
View all products
-
Epigenetic Reader Domain Degraders
(29)
View all products
-
Epigenetic Reader Domain Controls
(12)
View all products
-
Epigenetic Reader Domain Substrate
(1)
View all products
-
Epigenetic Reader Domain Ligands
(5)
View all products
-
Epigenetic Reader Domain Related Products (447)
Related Products (447)
-
BRD4 Inhibitor-32
0 ImagesCat. No.: HY-160636CAS No.: 1445992-86-8BRD4 Inhibitor-32 (example 15) is a BRD4 inhibitor that can be used in acute kidney disease and chronic kidney disease research.
-
ENL/AF9 YEATS-IN-1
0 ImagesCat. No.: HY-188074CAS No.: 2657651-10-8ENL/AF9 YEATS-IN-1 is a ENL/AF9 YEATS domain inhibitor. ENL/AF9 YEATS-IN-1 suppresses oncogene expression in cells by inhibiting the ENL/AF9 YEATS domain. ENL/AF9 YEATS-IN-1 can be used in leukemia research.
-
Revumenib (Standard)
0 ImagesCat. No.: HY-136175RCAS No.: 2169919-21-3Synonyms: SNDX-5613 (Standard)Revumenib (Standard) is the analytical standard of Revumenib (HY-136175). This product is intended for research and analytical applications. Revumenib (SNDX-5613) is a potent and specific Menin-MLL inhibitor with a binding Ki of 0.149 nM and a cell based IC50 of 10-20 nM. Revumenib can be used for the research of MLL-rearranged (MLL-r) acute leukemias, including acute lymphoblastic leukemia (ALL) and acute myeloid leukemia (AML).
-
F2276-0106
0 ImagesCat. No.: HY-153144CAS No.: 922054-57-7F2276-0106 is a biochemical reagent targeting the PCAF bromodomain (PDB 5FDZ). F2276-0106 is predicted to have good cell permeability and oral absorption, with physicochemical properties consistent with Lipinski's rule of five. F2276-0106 can be used in cancer-related research.
-
Y06036 (Standard)
0 ImagesCat. No.: HY-111502RCAS No.: 1832671-96-1
-
Naphthol AS-E (Standard)
0 ImagesCat. No.: HY-104068RCAS No.: 92-78-4Naphthol AS-E (Standard) is the analytical standard of Naphthol AS-E (HY-104068). This product is intended for research and analytical applications. Naphthol AS-E is a potent and cell-permeable inhibitor of KIX-KID interaction. Naphthol AS-E directly binds to the KIX domain of CBP (Kd:8.6 μM), blocks the interaction between the KIX domain and the KID domain of CREB with IC50 of 2.26 μM. Naphthol AS-E can be used for cancer research.
-
MZ 1 (Standard)
0 ImagesCat. No.: HY-107425RCAS No.: 1797406-69-9MZ 1 (Standard) is the analytical standard of MZ 1 (HY-107425). This product is intended for research and analytical applications. MZ 1 is a PROTAC connected by ligands for von Hippel-Lindau and BRD4. MZ 1 potently and rapidly induces reversible, long-lasting, and selective removal of BRD4 over BRD2 and BRD3. Kds of 382/120, 119/115, and 307/228 nM for BRD4 BD1/2, BRD3 BD1/2, and BRD2 BD1/2, respectively.
-
Menin-MLL-IN-36
0 ImagesCat. No.: HY-186044CAS No.: 2654078-52-9Menin-MLL-IN-36 (compound 398) is an inhibitor of menin/MLL protein/protein interaction with an IC50 value of 0.043 μM in MEIS1 mRNA expression. Menin-MLL-IN-36 can be used in the research of cancer, myelodysplastic syndrome (MDS), myeloproliferative neoplasms (MPN), and diabetes.
-
BET-IN-24
0 ImagesCat. No.: HY-160446CAS No.: 2407658-21-1Bet-in-24 (example 2) is a bromodomain and extra-terminal (BET) inhibitor. BET-IN-24 can be used in the study of virology, heart failure, inflammation, central nervous system (CNS) diseases and many cancers
-
E-7386 (Standard)
0 ImagesCat. No.: HY-111386RCAS No.: 1799824-08-0
-
BI-7273 (Standard)
0 ImagesCat. No.: HY-100351RCAS No.: 1883429-21-7BI-7273 (Standard) is the analytical standard of BI-7273 (HY-100351). This product is intended for research and analytical applications. BI-7273 is a selective, and cell-permeable BRD9 inhibitor, with an IC50 and a Kd of 19 and 0.75 nM; also shows high effect on BRD7, with an IC50 and a Kd of 117 nM and 0.3 nM.
-
GSK9311 (Standard)
0 ImagesCat. No.: HY-100729RCAS No.: 1923851-49-3GSK9311 (Standard) is the analytical standard of GSK9311 (HY-100729). This product is intended for research and analytical applications. GSK9311, a less active analogue of GSK6853, can be used as a negative control. GSK9311 inhibits BRPF bromodomain with pIC50 values of 6.0 and 4.3 for BRPF1 and BRPF2, respectively.
-
GSK8573 (Standard)
0 ImagesCat. No.: HY-107477RCAS No.: 1693766-04-9GSK8573 (Standard) is the analytical standard of GSK8573 (HY-107477). This product is intended for research and analytical applications. GSK8573 is an inactive control compound for GSK2801 (acetyl-lysine competitive inhibitor of BAZ2A and BAZ2B bromodomains). GSK8573 has binding activity to BRD9 with a Kd value of 1.04 μM and is inactive against BAZ2A/B and other bromodomain familiy. GSK8573 can be used as a structurally related negative control compound in biological experiments.
-
GNE-781 (Standard)
0 ImagesCat. No.: HY-108696RCAS No.: 1936422-33-1GNE-781 (Standard) is the analytical standard of GNE-781 (HY-108696). This product is intended for research and analytical applications. GNE-781 is an orally active, highly potent and selective CBP inhibitor with an IC50 of 0.94 nM in TR-FRET assay. GNE-781 also inhibits BRET and BRD4(1) with IC50s of 6.2 nM and 5100 nM, respectively. GNE-781 displays antitumor activity in an MOLM-16 AML xenograft model.
-
Curcumin-d3
0 ImagesCat. No.: HY-N0005S1Synonyms: Diferuloylmethane-d3; Natural Yellow 3-d3; Turmeric yellow-d3Curcumin-d3 (Diferuloylmethane-d3 ) is deuterium labeled Curcumin (HY-N0005). Curcumin (Diferuloylmethane), a natural phenolic compound, is a p300/CREB-binding protein-specific inhibitor of acetyltransferase, represses the acetylation of histone/nonhistone proteins and histone acetyltransferase-dependent chromatin transcription. Curcumin is a photosensitizer against microorganisms. Curcumin shows inhibitory effects on NF-κB and MAPKs, and has diverse pharmacologic effects including anti-inflammatory, antioxidant, antiproliferative and antiangiogenic activities. Curcumin induces stabilization of Nrf2 protein through Keap1 cysteine modification.
-
GNE-049 (Standard)
0 ImagesCat. No.: HY-108435RCAS No.: 1936421-41-8GNE-049 (Standard) is the analytical standard of GNE-049 (HY-108435). This product is intended for research and analytical applications. GNE-049 is a highly potent and selective CBP inhibitor with an IC50 of 1.1 nM in TR-FRET assay. GNE-049 also inhibits BRET and BRD4(1) with IC50s of 12 nM and 4200 nM, respectively.
-
CeMMEC1 (Standard)
0 ImagesCat. No.: HY-111445RCAS No.: 440662-09-9
-
EML 425 (Standard)
0 ImagesCat. No.: HY-110263RCAS No.: 1675821-32-5
